Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?

BACKGROUND: We lack tools to predict treatment and survival outcomes in patients receiving additional BCG therapy as a bladder-preserving therapy in high grade/T1, Tis NMIBC patients who showed persistent/recurrent tumors at three-month follow-up. OBJECTIVES: To assess the predictors of additional B...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsawy, Amr A., Laymon, Mahmoud, Mansour, Islam, Elghareeb, Ahmed, Harraz, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Oncology/Reconstruction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373613/
https://www.ncbi.nlm.nih.gov/pubmed/37521452
http://dx.doi.org/10.1080/2090598X.2023.2190687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373613/
https://www.ncbi.nlm.nih.gov/pubmed/37521452
http://dx.doi.org/10.1080/2090598X.2023.2190687

Ejemplares similares